The US federal authorities have approved the use of the Pfizer BioNTech vaccine for children between the ages of 5 and 11, so that including them can now be protected against a possible infection, but it will take some time until the European authorities offer a similar certification.
“US: Pfizer-BioNTech vaccine approved for emergency use in children aged 5 to 11 years
The US Food and Drug Administration (FDA) has authorized Pfizer-BioNTech's Comirnaty vaccine for emergency use in children aged 5 to 11 years.
Important:
Efficacy – The immune response in children aged 5 to 11 years was comparable to that of people aged 16 to 25 years. In addition, the vaccine was found to be 90,7% effective in preventing COVID-19 in children aged 5 to 11 years.
Safety – The safety of the vaccine was studied in approximately 3.100 children aged 5 to 11 who received the vaccine, and no serious side effects were detected in the study.
Administration – The primary vaccination schedule for children aged 5 to 11 years consists of two doses, 3 weeks apart, but is a lower dose (10 micrograms) than that used for people aged 12 years and older (30 micrograms )."
